{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:14:20Z","timestamp":1766405660970,"version":"3.48.0"},"reference-count":68,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Background: Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. Arterial hypertension represents the leading modifiable risk factor for cardiovascular morbidity and mortality globally. Their coexistence is frequent, affecting approximately 40\u201360% of adults with HCM, yet the implications of this overlap remain insufficiently investigated. Methods: We conducted a narrative review of the existing literature addressing the clinical profile and management strategies in patients with concomitant HCM and hypertension. Particular emphasis was placed on pharmacologic treatment and the role of emerging therapies for this population. Results: Patients with both conditions are generally older, with more cardiometabolic comorbidities and greater functional limitation than those with isolated HCM. Hypertension may confound diagnosis and is linked to a higher prevalence of atrial fibrillation and stroke. Its effect on ventricular arrhythmias, sudden cardiac death and mortality is less clear. Management is challenging, as vasodilatory antihypertensives can exacerbate left ventricular outflow tract obstruction. \u03b2-blockers and non-dihydropyridine calcium channel blockers are preferred, while novel agents such as myosin inhibitors and SGLT2 inhibitors show potential but require further study. Conclusions: The coexistence of HCM and hypertension is frequent but insufficiently studied, with major implications for diagnosis and treatment. Further research is essential to optimize management and outcomes.<\/jats:p>","DOI":"10.3390\/diseases14010001","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T11:43:31Z","timestamp":1766403811000},"page":"1","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Coexistence of Hypertrophic Cardiomyopathy and Arterial Hypertension: Current Insights and Future Directions"],"prefix":"10.3390","volume":"14","author":[{"given":"Vasiliki","family":"Katsi","sequence":"first","affiliation":[{"name":"First Cardiology Department, Hippokration General Hospital of Athens, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantia","family":"Papadomarkaki","sequence":"additional","affiliation":[{"name":"First Cardiology Department, Hippokration General Hospital of Athens, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Manousiadis","sequence":"additional","affiliation":[{"name":"Emergency Department, Hippokration General Hospital of Athens, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Epameinondas","family":"Triantafyllou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hippokration General Hospital of Athens, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5598-9950","authenticated-orcid":false,"given":"Christos","family":"Fragoulis","sequence":"additional","affiliation":[{"name":"First Cardiology Department, Hippokration General Hospital of Athens, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-6725","authenticated-orcid":false,"given":"Konstantinos","family":"Tsioufis","sequence":"additional","affiliation":[{"name":"First Cardiology Department, Hippokration General Hospital of Athens, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC)","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"E007230","DOI":"10.1161\/CIRCHEARTFAILURE.120.007230","article-title":"Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy: An Analysis of the International Sarcomeric Human Cardiomyopathy Registry","volume":"13","author":"Canepa","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO)","volume":"45","author":"McCarthy","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.recesp.2017.06.034","article-title":"Challenges and Controversies in Hypertrophic Cardiomyopathy: Clinical, Genomic and Basic Science Perspectives","volume":"71","author":"Pasipoularides","year":"2018","journal-title":"Rev. Espa\u00f1ola De Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100367","DOI":"10.1016\/j.ahjo.2024.100367","article-title":"Clinical course of adults with co-occurring hypertrophic cardiomyopathy and hypertension: A scoping review","volume":"39","author":"Arabadjian","year":"2024","journal-title":"Am. Heart J. Plus Cardiol. Res. Pract."},{"key":"ref_7","first-page":"42","article-title":"Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy\/Myocarditis registry","volume":"9","author":"Lopes","year":"2022","journal-title":"Eur. Heart J.-Qual. Care Clin. Outcomes"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/eurheartj\/ehx527","article-title":"Women with hypertrophic cardiomyopathy have worse survival","volume":"38","author":"Geske","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1136\/heartjnl-2016-309843","article-title":"Comparison of hypertrophic cardiomyopathy in Afro-Caribbean versus white patients in the UK","volume":"102","author":"Sheikh","year":"2016","journal-title":"Heart"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e14614","DOI":"10.7717\/peerj.14614","article-title":"The impact of hypertension on the prognosis of patients with hypertrophic cardiomyopathy: A single-center retrospective study","volume":"11","author":"Wang","year":"2023","journal-title":"PeerJ"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","article-title":"Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review","volume":"79","author":"Maron","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1093\/eurheartj\/ehaf324","article-title":"Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model","volume":"46","author":"Baka","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1161\/CIRCULATIONAHA.123.065037","article-title":"Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy","volume":"148","author":"Rowin","year":"2023","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"euae177","DOI":"10.1093\/europace\/euae177","article-title":"Understanding the incidence of atrial fibrillation and stroke in hypertrophic cardiomyopathy patients: Insights from Danish nationwide registries","volume":"26","author":"Schjerning","year":"2024","journal-title":"Europace"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1136\/heartjnl-2016-309672","article-title":"Predictors of atrial fibrillation in hypertrophic cardiomyopathy","volume":"103","author":"Guttmann","year":"2017","journal-title":"Heart"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"E009796","DOI":"10.1161\/CIRCEP.120.009796","article-title":"Development and Validation of a Clinical Predictive Model for Identifying Hypertrophic Cardiomyopathy Patients at Risk for Atrial Fibrillation: The HCM-AF Score","volume":"14","author":"Carrick","year":"2021","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10654-019-00593-4","article-title":"Blood pressure, hypertension and the risk of sudden cardiac death: A systematic review and meta-analysis of cohort studies","volume":"35","author":"Pan","year":"2020","journal-title":"Eur. J. Epidemiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"28499","DOI":"10.1038\/s41598-025-14357-6","article-title":"Left ventricular septal convexity in differentiating hypertrophic cardiomyopathy from hypertensive heart disease\u2014A cardiac magnetic resonance study","volume":"15","author":"Tarkiainen","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/ehjci\/jev329","article-title":"Prevalence and predictors of asymmetric hypertensive heart disease: Insights from cardiac and aortic function with cardiovascular magnetic resonance hypertension hypertrophy hypertrophic cardiomyopathy cardiac magnetic resonance","volume":"17","author":"Rodrigues","year":"2016","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.crad.2024.08.028","article-title":"Hypertension and its association to phenotype on left ventricular function in hypertrophic cardiomyopathy patients assessed by cardiovascular magnetic resonance imaging","volume":"79","author":"Yang","year":"2024","journal-title":"Clin. Radiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jcmg.2019.08.030","article-title":"Myocardial Efficiency: A Fundamental Physiological Concept on the Verge of Clinical Impact","volume":"13","author":"Harms","year":"2020","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11886-025-02239-2","article-title":"Polygenic Risk Scores in Dilated Cardiomyopathy: Towards the Future","volume":"27","author":"Kramarenko","year":"2025","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.109.930636","article-title":"Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: Preliminary validation in humans","volume":"122","author":"Flett","year":"2010","journal-title":"Circulation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"16977","DOI":"10.1038\/s41598-024-67979-7","article-title":"Microcirculatory dysfunction in hypertrophic cardiomyopathy with chest pain assessed by angiography-derived microcirculatory resistance","volume":"14","author":"Lu","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"C130","DOI":"10.1093\/eurheartjsupp\/suad015","article-title":"Diagnostic and prognostic role of late gadolinium enhancement in cardiomyopathies","volume":"25","author":"Aquaro","year":"2023","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jacc.2008.08.064","article-title":"Noninvasive Detection of Fibrosis Applying Contrast-Enhanced Cardiac Magnetic Resonance in Different Forms of Left Ventricular Hypertrophy: Relation to Remodeling","volume":"53","author":"Rudolph","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Talle, M.A., Doubell, A.F., Robbertse, P.P.S., Lahri, S., and Herbst, P.G. (2023). Cardiac Morphology, Function, and Left Ventricular Geometric Pattern in Patients with Hypertensive Crisis: A Cardiovascular Magnetic Resonance-Based Study. J. Cardiovasc. Dev. Dis., 10.","DOI":"10.3390\/jcdd10090367"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11897-020-00481-z","article-title":"Cardiovascular Magnetic Resonance for the Differentiation of Left Ventricular Hypertrophy","volume":"17","author":"Burrage","year":"2020","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Neisius, U., Myerson, L., Fahmy, A.S., Nakamori, S., El-Rewaidy, H., Joshi, G., Duan, C., Manning, W.J., and Nezafat, R. (2019). Cardiovascular magnetic resonance feature tracking strain analysis for discrimination between hypertensive heart disease and hypertrophic cardiomyopathy. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0221061"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zdravkovic, M., Klasnja, S., Popovic, M., Djuran, P., Mrda, D., Ivankovic, T., Manojlovic, A., Koracevic, G., Lovic, D., and Popadic, V. (2022). Cardiac Magnetic Resonance in Hypertensive Heart Disease: Time for a New Chapter. Diagnostics, 13.","DOI":"10.3390\/diagnostics13010137"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Durante, A., Mazzapicchi, A., and Redaelli, M.B. (2024). Systemic and Cardiac Microvascular Dysfunction in Hypertension. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252413294"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s12350-022-03040-2","article-title":"Coronary microvascular disease in hypertrophic and infiltrative cardiomyopathies","volume":"30","author":"Giannopoulos","year":"2023","journal-title":"J. Nucl. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12968-016-0223-8","article-title":"Microvascular ischemia in hypertrophic cardiomyopathy: New insights from high-resolution combined quantification of perfusion and late gadolinium enhancement","volume":"18","author":"Villa","year":"2016","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1161\/CIRCIMAGING.108.840975","article-title":"The prognostic implications of cardiovascular magnetic resonance","volume":"2","author":"Flett","year":"2009","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jacc.2005.10.050","article-title":"Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy","volume":"47","author":"Olivotto","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"21936","DOI":"10.1161\/JAHA.120.021936","article-title":"Prognostic Value of Transthoracic Doppler Echocardiography Coronary Flow Velocity Reserve in Patients With Asymmetric Hypertrophic Cardiomyopathy","volume":"10","author":"Tesic","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"v256","DOI":"10.1093\/eurheartjsupp\/suaf077","article-title":"ANMCO position paper \u2018Hypertrophic cardiomyopathy: From diagnosis to treatment","volume":"27","author":"Chimenti","year":"2025","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.amjcard.2023.10.074","article-title":"Medical Treatment Strategies for Hypertrophic Cardiomyopathy","volume":"212","author":"Hutt","year":"2024","journal-title":"Am. J. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.echo.2022.09.008","article-title":"Metoprolol Improves Left Ventricular Longitudinal Strain at Rest and during Exercise in Obstructive Hypertrophic Cardiomyopathy","volume":"36","author":"Dybro","year":"2023","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa2504654","article-title":"Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy","volume":"393","author":"Maron","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","article-title":"Effect of \u03b2-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction","volume":"78","author":"Palau","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1172\/JCI115061","article-title":"Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole","volume":"87","author":"Gwathmey","year":"1991","journal-title":"J. Clin. Investig."},{"key":"ref_45","unstructured":"Epstein, S.E., and Rosing, D.R. (2025, November 29). CURRENT TOPICS Verapamil: Its Potential for Causing Serious Complications in Patients with Hypertrophic Cardiomyopathy. Available online: http:\/\/ahajournals.org."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Derda, A.A., Abelmann, M., Sonnenschein, K., Sieweke, J.-T., Bavendiek, U., Bauersachs, J., Thum, T., and Berliner, D. (2024). Discontinuation of afterload-reducing drugs decreases left ventricular outflow tract obstruction in hypertrophic obstructive cardiomyopathy. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1403422"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jchf.2023.07.030","article-title":"Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM Trial","volume":"12","author":"Wang","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jchf.2023.12.021","article-title":"Are Cardiac Myosin Inhibitors Useful in Patients with Hypertrophic Obstructive Cardiomyopathy and Comorbid Hypertension?","volume":"12","author":"Sikand","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"ytae450","DOI":"10.1093\/ehjcr\/ytae450","article-title":"Accelerated hypertension following mavacamten introduction in severe obstructive hypertrophic cardiomyopathy with hypertension: A case report","volume":"8","author":"Maurizi","year":"2024","journal-title":"Eur. Heart J. Case Rep."},{"key":"ref_50","first-page":"E895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"100843","DOI":"10.1016\/j.jacadv.2024.100843","article-title":"Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Mortality in Hypertrophic Cardiomyopathy","volume":"3","author":"Aglan","year":"2024","journal-title":"JACC Adv."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.cardfail.2024.08.026","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of SOtaglifloziN in Patients with SymptomATic obstructive And non-obstructive Hypertrophic CardioMyopathy (SONATA-HCM)","volume":"30","author":"Ho","year":"2024","journal-title":"J. Card. Fail."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Brata, R., Pascalau, A.V., Fratila, O., Paul, I., Muresan, M.M., Camarasan, A., and Ilias, T. (2024). Hemodynamic Effects of SGLT2 Inhibitors in Patients with and Without Diabetes Mellitus\u2014A Narrative Review. Healthcare, 12.","DOI":"10.3390\/healthcare12232464"},{"key":"ref_57","first-page":"ehaf784.982","article-title":"Impact of SGLT2-inhibitors on cardiac function and structural changes in patients with heart failure and reduced ejection fraction\u2014Results from the REWIN-HFrEF Study","volume":"46","author":"Inciardi","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic. Transl. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"108861","DOI":"10.1016\/j.pharmthera.2025.108861","article-title":"Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure","volume":"270","author":"Armillotta","year":"2025","journal-title":"Pharmacol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/heartjnl-2015-308343","article-title":"Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial","volume":"102","author":"Axelsson","year":"2016","journal-title":"Heart"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jchf.2013.09.001","article-title":"Effects of Losartan on Left Ventricular Hypertrophy and Fibrosis in Patients With Nonobstructive Hypertrophic Cardiomyopathy","volume":"1","author":"Shimada","year":"2013","journal-title":"JACC Heart Fail."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2353\/jmoldx.2009.080082","article-title":"The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy","volume":"11","author":"Penicka","year":"2009","journal-title":"J. Mol. Diagn."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41591-021-01505-4","article-title":"Valsartan in early-stage hypertrophic cardiomyopathy: A randomized phase 2 trial","volume":"27","author":"Ho","year":"2021","journal-title":"Nat. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s11897-021-00526-x","article-title":"Sex Differences in Hypertrophic Cardiomyopathy: Interaction With Genetics and Environment","volume":"18","author":"Butters","year":"2021","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12265-016-9681-5","article-title":"Evaluation of the Mayo Clinic Phenotype-Based Genotype Predictor Score in Patients with Clinically Diagnosed Hypertrophic Cardiomyopathy","volume":"9","author":"Murphy","year":"2016","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/CIRCGENETICS.112.963363","article-title":"Toronto Hypertrophic Cardiomyopathy Genotype Score for Prediction of a Positive Genotype in Hypertrophic Cardiomyopathy","volume":"6","author":"Gruner","year":"2013","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jacc.2021.08.015","article-title":"On-Treatment Blood Pressure and Cardiovascular Outcomes in Adults With Hypertension and Left Ventricular Hypertrophy","volume":"78","author":"Lee","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_68","first-page":"e114","article-title":"2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"152","author":"Johnson","year":"2025","journal-title":"Circulation"}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/1\/1\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:11:46Z","timestamp":1766405506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/1\/1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["diseases14010001"],"URL":"https:\/\/doi.org\/10.3390\/diseases14010001","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]}}}